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A systematic review of geographical
variation in access to chemotherapy
Charlotte Chamberlain*, Amanda Owen-Smith, Jenny Donovan and William Hollingworth
Abstract
Background: Rising cancer incidence, the cost of cancer pharmaceuticals and the introduction of the Cancer Drugs
Fund in England, but not other United Kingdom(UK) countries means evidence of ‘postcode prescribing’ in cancer
is important. There have been no systematic reviews considering access to cancer drugs by geographical
characteristics in the UK.
Methods: Studies describing receipt of cancer drugs, according to healthcare boundaries (e.g. cancer network [UK])
were identified through a systematic search of electronic databases and grey literature. Due to study heterogeneity
a meta-analysis was not possible and a narrative synthesis was performed.
Results: 8,780 unique studies were identified and twenty-six included following a systematic search last updated in
2015. The majority of papers demonstrated substantial variability in the likelihood of receiving chemotherapy
between hospitals, health authorities, cancer networks and UK countries (England and Wales). After case-mix
adjustment, there was up to a 4–5 fold difference in chemotherapy utilisation between the highest and lowest
prescribing cancer networks. There was no strong evidence that rurality or distance travelled were associated with
the likelihood of receiving chemotherapy and conflicting evidence for an effect of travel time.
Conclusions: Considerable variation in chemotherapy prescribing between healthcare boundaries has been
identified. The absence of associations with natural geographical characteristics (e.g. rurality) and receipt of
chemotherapy suggests that local treatment habits, capacity and policy are more influential.
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Background
Cancer is the leading cause of mortality in the United
Kingdom (UK) [1]. Cancer incidence is rising and so too
is the proliferation of high-cost, life-extending cancer
drugs. There are potential restrictions on access to can-
cer drugs in the UK National Health Service (NHS) at a
number of levels: national policy; regional and local
commissioner and provider activity; clinician prescribing
preferences, and individual patient care seeking behav-
iour [2–4]. The UK was ranked 12th of 14 European
countries for the prescribing of cancer pharmaceuticals
launched in the last 5 years [5]. Within the UK, there
has been considerable attention on regional variation in
prescribing [6, 7] and this was a major factor in the es-
tablishment of the National Institute for Health and Care
Excellence (NICE) in 1999; an attempt to ameliorate the
so called, ‘postcode lottery of prescribing’. The recent re-
structuring of the NHS, with a move to Strategic Clinical
Networks, (SCNs) instead of Cancer Networks; the con-
tinued trend for centralisation of cancer services to drive
quality and efficiency improvements, and divergent cancer
drugs funding policy, with the establishment of the Cancer
Drugs Fund in England, but not in Wales, Scotland or
Northern Ireland, are all important changes that may im-
pact on equity of cancer pharmaceutical prescribing by
geographical region.
‘Access’ to cancer drugs, encompasses the quality, equit-
ability, acceptability and availability of chemotherapy for
those in need [8]. The term chemotherapy is frequently
used in the literature to represent anti-cancer drugs, al-
though chemotherapy can represent any-drug therapy or
specific anti-cancer therapies that exclude hormonal
treatments or radiopharmaceuticals for instance. For the
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purpose of this paper chemotherapy is used interchange-
ably with anti-cancer drug therapy to capture all relevant
papers. It is challenging to measure access and therefore
rates of utilisation alone are frequently used as a proxy.
Utilisation may appear appropriate for the size of popula-
tion under study, but instead represent health demand, ra-
ther than clinically assessed ‘health need’ and in some
circumstances, mask inequitable use of services [9]. Fur-
thermore, variation may result from explicit resource allo-
cation decisions, such as the decision by Wales not to
have a Cancer Drugs Fund, prioritising spend earlier in
the cancer pathway. However, poor uptake of cancer drugs
has been associated with reduced life expectancy in correl-
ational studies [10] and therefore, variation in use or ac-
cess to these drugs where it is unwarranted according to
clinical need may represent a threat to health. Variation
may be considered inequitable and contrary to the NHS
constitution [11] if it is the result of opaque healthcare
boundary differences in provision or ‘natural’ geographical
barriers (e.g. distance).
Three systematic [12–14] and seven literature reviews
[3, 4, 15–19] have considered diffusion of pharmaceuti-
cals and innovations in developed and developing na-
tions alongside distribution and uptake of other cancer
treatment modalities. However, none of these reviews
are systematic accounts of barriers to access to cancer
pharmaceuticals. The international literature includes
surveys of patient perceptions of the role of rurality or
distance to treatment in their chemotherapy decision-
making and both found evidence that the distance to
treatment has an influence on uptake or compliance
with treatment options for their cancer [20, 21]. Widely
cited, grey literature publications in the UK, comparing
chemotherapy utilisation by healthcare geographical area:
England vs Wales vs Scotland; Strategic Health Authority
(SHA) or Primary Care Trust level, have found large vari-
ation [22, 23]. Exploring and quantifying this variation and
the reasons for variation in chemotherapy prescribing by
geographical area is therefore important for quality, equit-
able care for NHS patients.
We aimed to systematically identify published studies
considering geographical barriers to use of cancer phar-
maceuticals in the UK NHS.
Methods
Search Strategy
The review methodology was performed in accordance
with the Centre for Reviews and Dissemination (National
Institute for Health Research [NIHR]) guidance on sys-
tematic reviews [24, 25] and reported according to the
PRISMA statement, checklist (Additional file 1) and flow-
diagram [26]. A systematic literature search was carried
out using electronic databases, electronic citation tracking
(ISI Web of Knowledge citation indexes), hand-searching
of references identified in eligible studies, and grey-
literature searching. The search strategy was tailored to
each electronic database to account for differing wildcards
and system features. Search terms included key words,
synonyms and MeSH terms for cancer drugs OR access
OR inequality. The search strategy was written by the first
author and refined by a medical librarian (CB) and an ex-
perienced systematic reviewer (MB). Scoping took place
between September and December 2012, with a formal
search run by the experienced systematic reviewer (MB)
in March 2013. An update of the electronic database
search was conducted in July 2015 by the first author
(CC). A list of the nine interrogated electronic databases,
including MEDLINE and EMBASE is available in the
Additional file 2 along with the search strategy. Informal
approaches are also described in the Additional file 2 and
included Google and specific health and health policy
websites (last updated in July 2013).
The search strategy was kept deliberately broad to in-
clude all potential barriers to chemotherapy utilisation,
including policy and system barriers; environmental con-
text obstacles (including geographical barriers), and
challenges resulting from variation in individual patient
characteristics (such as age or gender) affecting profes-
sional prescribing and appropriateness of services.
Study Eligibility
Papers were classified according to three themes: ‘policy/
systems’, ‘geographical’ and ‘individual patient characteris-
tics’, and where eligible for more than one theme, were in-
cluded in all suitable themes. Eligible studies which did
not have geographical exposure variables were excluded
from this report, for future study under other theme head-
ings. The primary outcome measure was receipt of
chemotherapy, defined by prescribing data.The exposure
was geographical healthcare boundary (e.g. cancer net-
work, strategic health authority, acute hospital trust), or
other measured geographical characteristic, such as popu-
lation density (rurality), distance to treatment centre, or
travel-time to treatment centre. Inclusion criteria inclu-
deddescription of cancer pharmaceutical prescribing in
adults (>18 years) in the UK NHS. All cancer drug pre-
scribing, including reports of sub-optimal or delayed pre-
scribing were included. Geographical chracteristics of
natural geographical boundaries (testing the influence of
rurality, time or distance to treatment) or healthcare
geographical boundaries (including healthcare designated
areas arranged by policy or organisation, such as acute
trust or cancer network) and their influence on chemo-
therapy receipt were all eligible for inclusion. There were
no time or language limitations to the eligibility criteria.
Exclusion criteria included papers which focused on all
pharmaceuticals and not primarily cancer pharmaceuti-
cals, conference proceedings, quantitative papers with <30
Chamberlain et al. BMC Cancer  (2016) 16:1 Page 2 of 15
participants or commentary pieces. Study quality was con-
sidered, but studies were not excluded on grounds of
quality alone.
Study Selection
Title and abstract screening was performed by CC using
EndNote software, with independent double-screening
(JB) of a sample of abstracts to assess reliability (5 % of
CC excluded abstracts and all CC included abstracts). In
the event of uncertainty, studies were included for full-
text review. Disagreements were to be resolved with dis-
cussion and consensus between JB, CC and WH.
Data Extraction
Pre-defined data items, as per the STrengthening the
Reporting of OBservational studies in Epidemiology
(STROBE) checklist headings (e.g. study design, outcome
and exposure variables, methods, analysis approach and
results amongst others) and study description (author,
year, title, journal), whether the manuscript was peer-
reviewed, and whether it met the eligibility criteria and if
not, why not (reason for exclusion) were extracted from
each full-text study in Microsoft Access (CC). Principle
summary measures included Odds Ratios (odds of re-
ceipt of chemotherapy by the geographical exposure) as
well as descriptive statistics with proportions and per-
centages and appropriate statistical tests (e.g. t-test).
Analysis
Reporting clarity was evaluated with the STROBE obser-
vational checklist and methodological quality with the
NICE adapted Graphical Appraisal Tool for Epidemio-
logical studies (GATE) [27]. Narrative synthesis was per-
formed by the first reviewer (CC) and verified by the
senior author (WH). The objectives of the systematic re-
view were peer-reviewed as part of the NIHR Doctoral
Fellowship award. A protocol was not publicly listed.
Results
5,987 unique titles and abstracts (5,961 identified from
electronic bibliographic databases and 80 from other
sources) were screened, after removal of duplicates (54)
in March 2013. An additional 2,894 studies were identi-
fied from a repeat of the systematic search strategy of
the included electronic databases (July 2015, 2,793 after
removal of duplicates [101]). Of 344 double-screened in-
cluded and excluded abstracts, one initially excluded
paper was included in the final analysis. Initial exclusion
referred the paper to a different theme and was an error
based on mistaking the use of geographical exposure
variables, as well as individual characteristics, as part of
the study design. Twenty six papers, following the update,
were included in the analysis: 16 peer-reviewed and 10
from the grey literature (Fig. 1). Nine grey literature
studies were annual National Lung Cancer Audit (NLCA)
reports [28]. For simplicity, only one NLCA report is pre-
sented in the tables and referenced in the report. All earl-
ier reports follow the same template and are available
online. Six included studies referred to multiple cancer
types [6, 29–33] 15 to lung cancer only [34–39] four to
colorectal cancer [40–43], and one in prostate cancer [44].
Table 1 presents study characteristics and Tables 2–7
present the key findings. Additional file 3: Table S1 de-
scribes the reporting quality and Additional file 4: Table
S2–S8 the methodological quality of the included studies.
Characteristics of included studies
Twenty-four cohort studies [28–32, 34–43, 45], one cor-
relational study [6] and two before and after studies
[30, 33] were included in the review. Identified geograph-
ical exposure variables included: travel time or distance to
a cancer treatment centre; rurality; and geographical area,
defined by healthcare boundaries (e.g. acute hospital trust,
cancer network or SHA). The majority of included studies
relied on analysis of cancer registry data, with or without
linkage to hospital records for co-morbidities [29, 31, 35–
38, 40–42, 44]. Remaining data sources were IMS Health
hospital prescribing data [6, 30, 33], local hospital data
[32] and nationally collected audit data [34, 39, 46].
Populations of includedstudies varied. The majority of
cancer registry studies used clinical or histologically con-
firmed cancers analysed in aggregate [31, 32, 36–38, 40]
or separately [34, 35, 46]. One study restricted to histo-
logically confirmed cancers only [39]. A further eight
studies appeared to use both histological and clinically
confirmed cancers together, but did not make this expli-
cit [6, 29, 30, 33, 41–44].The majority of peer-reviewed
studies excluded death certificated only (DCO) cancers
[29, 31, 32, 35–39, 44]. Six peer-reviewed studies did not
comment [30, 34, 40–43]. It is likely, based on study de-
signs which relied on prescribing data in aggregate rather
than individuals, that DCO cases were excluded in the
non-peer reviewed literature [6, 33, 46]. Five studies ex-
cluded NHS hospital trusts and (their patients) from study
where there were small numbers (<5 patients over study
period [41, 43]; <30 patients [39]; <1 % of patients in the
cohort [36]; or trusts with <1 % of treatment for each can-
cer type) [31]. Sample sizes ranged from 126 [32] to
117,097 participants, where stated [31].
Four different tools measuring deprivation were used in
the included studies: Index of Multiple Deprivation (IMD)
[28, 36, 38, 40, 42] Carstairs [29, 41], DepCat [43], Town-
send [37, 39] or none [6, 32, 33, 45]. Rurality was defined
and measured in different ways. Campbell et al. [29] defined
rurality by the ‘distance to the nearest cancer centre in
Aberdeen or Inverness, which, based on previous research
implied low settlement size and rurality’. Laing described
rural areas according to a “pre-existing classification” of an
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area as “accessible rural or remote-rural” (Highland and
Western Isles) and compared it with Lothian, a “large urban
or other urban” area. [45] Where these definitions of the
rurality of the population are derived from is not included,
though it is implied this may use the rural urban classifica-
tion used by the UK Government [47]. McLeod [41] and
Pitchforth et al. [43] defined ‘rurality’ using population
density (persons per hectare) based on census data, which
presumably coincides with Urban–rural classification, but
has not been assessed.
Most studies presented adjusted odds ratios of receiv-
ing chemotherapy, based on multivariable logistic re-
gression [29, 31, 34, 36, 37, 39–41, 43, 46] and/or crude
proportions of receipt of chemotherapy (or timeliness of
receipt of chemotherapy) [32] in eligible patients [6, 35,
38, 39, 45]. Twenty-one studies (including all NLCA) ad-
justed or stratified based on age, sex and deprivation
[28, 29, 31, 34–43]. One time-trend analysis presented
hazard ratios based on negative binomial regression and
was not adjusted for age, sex, stage of participants [30].
Disease stage was absent from fiveof these studies [30,
35, 36, 41, 43], with one of the four using ‘disease extent’,
which was not defined [35]. Performance status was only
adjusted for in a minority of reports: all being based on
NLCA data since 2009 [34, 39, 46], although attempts,
such as using co-morbidity with linkage to Hospital Epi-
sode Statistics (HES) databases and admission type
(elective or non-elective) were also used to approximate
performance status in other studies [29, 41, 43].
Reporting Clarity and Quality Assessment
The poorest reported areas were inclusion of a partici-
pant flow-chart; reporting of study design in the title or
abstract; description of study result generalizability and
missing data fields. Many papers did not report on ef-
forts to limit bias. Additional file 3: Table S1.
Fig. 1 Prisma diagram: access to cancer drugs in the NHS
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Table 1 Study characteristics
Author, Year Setting Data sources Participants Exposure Outcome Statistical methods
Cohort studies
Beckett ‘12 [34] England, Wales, Scotland,
Northern Ireland and
Jersey
National Lung
Cancer Audit
(NLCA) data ‘09
32,068 lung cancer participants
diagnosed histologically or clinically
and excluding cases diagnosed at
post-mortem. All cancer units included.
Cancer network Odds of receipt of
chemotherapy in
Small Cell Lung
Cancer (SCLC)
within one audit
year, by cancer
network.
Logistic regression adjusted for
age, sex, performance status,
stage and deprivation. IMD
deprivation index.
Campbell,
‘02 [29]
Grampian and Highland,
Scotland
Scottish Cancer
Registry ’95 to
‘96 and case
notes from
hospitals
1,314 colorectal and lung cancer
participants, excluding cases
diagnosed at post-mortem. All
cancer units included. Whether
participants were diagnosed
histologically and clinically:not
stated.
Distance to the
nearest cancer
centre
Odds of receipt of
chemotherapy within
one year of diagnosis
by distance travelled.
Logistic regression adjusted for
age, sex, deprivation, cancer
site and Dukes stage and
histology (lung: SCLC, NSCLC)
and ISS stage, health board
of residence, and mode of
presentation. Carstairs
deprivation index.
Cartman,
‘02 [35]
The 17 districts in
Yorkshire and South
Humber, England
Northern and
Yorkshire Cancer
Registry (NYCRIS)
‘86 to ‘94
22,654 lung cancer participants
diagnosed histologically or clinically
and excluding cases diagnosed at
post-mortem. All cancer units included.
Health Authority
District of
residence
Range, numbers
and percent of
eligible participants
receiving
chemotherapy
by health authority.
District variation measures
presented as a range in
numbers and percents.
Crawford,
‘12 [40]
The 17 districts in
Yorkshire and South
Humber, England
NYCRIS ’94 to ‘02 18,221 Colorectal cancer participants
diagnosed histologically or clinically.
Not stated whether cases diagnosed
at post-mortem were excluded. All
cancer units included.
Car travel time
to healthcare
provider
Odds of receipt of
chemotherapy
within 6 months
of diagnosis by
travel time.
Logistic Regression adjusted
for age, sex and tumour stage.
Analysis stratified by deprivation
and travel time with a test for
interaction. IMD deprivation score.
Crawford,
‘09 [36]
The 17 districts in
Yorkshire and South
Humber, England
NYCRIS ’94 to ’02 34,923 Lung Cancer participants
diagnosed histologically or clinically
and excluding cases diagnosed at
post-mortem. All cancer units included.
Car travel time Odds of receipt of
chemotherapy
within 6 months
of diagnosis by
travel time.
Logistic regression adjusted for
age and sex. Analysis stratified
by deprivation and travel time.
There was no adjustment for
disease stage. IMD deprivation
score.
Jack, ‘03 [37] South East England Thames Cancer
Registry: ’95
to ‘99
32,818 participants with lung cancer
confirmed histologically or clinically
and excluding cases diagnosed at
post-mortem. All cancer units included.
Health authority
of residence
Ranges and medians
reflecting variation
in receipt of
chemotherapy
by health authority.
The odds of receiving
chemotherapy by
health authority
calculated.
Health authority variation
presented as medians and
ranges. Multi-level logistic
regression (participants nested
in hospitals or health authorities)
adjusted for age, sex, histology,
deprivation, lung cancer incidence,
whether first hospital attended
was a radiotherapy centre,
hospital, tumour stage.
Townsend deprivation score.
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Table 1 Study characteristics (Continued)
Jones, ‘08 [31] The 17 districts in
Yorkshire and South
Humber, England
NYCRIS ’94 to ‘02 117,097 Lung, breast, colon, rectum,
ovary and prostate cancer participants,
excluding cases diagnosed at post-
mortem. Whether both histologically
and clinically diagnosed participants
were included was not stated. Units
which only rarely offered treatment were
excluded.
Travel time Odds of receipt
of chemotherapy
by travel time
Conditional logistic regression,
adjusted for age, sex, tumour
stage (where available),
“site-specific characteristics”
and deprivation. No tests for
interaction or trend were
performed. IMD deprivation
score.
Laing ‘14 [45] Scotland (Highland and
Western Isles and Lothian)
Information
Services Division
and regional
cancer datasets
2005 to 2010
3,308 men with prostate cancer who
received treatment for prostate cancer,
therefore Death Certified Only cases
not included. No sites documented
as excluded.
Rurality
determined as
Highland and
Western isles
resident compared
with Urban
(Lothian) residence.
Treatment receipt
compared by
NHS health area.
Receipt of
chemotherapy as
‘first treatment’
within the study
period.
Student t-test, Mann–Whitney U
test and two-sample Z test as
appropriate. Stratified by risk
group (e.g. low and intermediate
compared with high-risk and
metastatic). No deprivation indices.
McLeod, ‘99 [41] Scotland Hospital Discharge
Data SMR01
linked to General
Register Office
death records.
Jan ‘90 to
June ‘94
15,016 colorectal cancer participants.
Although not explicitly stated, it is
probable that participants diagnosed
histologically and clinically were
included and cases diagnosed at
post-mortem were excluded. Units
which only rarely offered treatment
were excluded.
Rurality of
participants’
place of residence
and hospital.
Odds of receipt of
chemotherapy
within 6 months
of first admission
by population
density of patients’
residence (rural/
urban) and by
each hospital trust.
Multilevel logistic regression
adjusting for age, sex, marital
status, deprivation, type of
admission, secondary diagnoses,
hospital characteristics (e.g.
chemotherapy availability) and
severe illness. The final model
was not clearly reported. Carstairs
deprivation indices.
Monkhouse,
‘13 [32]
England 2010-2011 118 participants with upper GI cancer.
Data from post-mortem necessarily
excluded as patients recruited were
from Multi-disciplinary meetings.
Hospital site,
defined as ‘hub’
tertiary hospital
or ‘spoke’ district
general hospital
Time to receipt of
chemotherapy
from first
multi-disciplinary
meeting.
Parametric two-tailed t-test. No
deprivation indices.
NLCA*’13 [28] England, Wales,
Scotland, N.Ireland
and Jersey Hospital
NLCA ’12 data 40,216 lung cancer participants
diagnosed histologically and excluding
cases diagnosed at post-mortem.
All cancer units included. Audit data
includes clinically diagnosed cases,
but not for outcomes reported here.
Cancer network
and hospital trust
Numbers, percentages
and Odds of receipt
of chemotherapy
in SCLC and Stage
III/IV NSCLC PS 0/1
participants by
hospital trust and
cancer network.
Logistic regression, adjusted for
age, sex, socioeconomic status,
performance status and stage by
cancer network or hospital trust.
No deprivation indices.
Patel, ‘07 [38] South East England Thames Cancer
Registry ‘94 to ‘03
67,312 participants diagnosed with
lung cancer histologically or clinically
and excluding cases diagnosed at
post-mortem. All cancer units included.
Cancer Network. Odds of receipt of
chemotherapy within
6 months of first
diagnosis by
cancer network.
Logistic regression, adjusted for
sex, age, type of lung cancer, cancer
stage and deprivation. Tests for
heterogeneity/trend were included
as appropriate across categorical
variables. IMD deprivation indices.
Paterson,
‘13 [42]
Southeast Scotland Southeast Scotland
Cancer Network
4960 colorectal cancer patients. No
mention of use of cases which are
Health board of
residence (in
Descriptive statistics
as well as odds
Logistic regression, adjusted for age,
sex, tumour site (colon or rectum),
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Table 1 Study characteristics (Continued)
colorectal database
2003-2009
death certified only. No sites recorded
as being excluded on base of size.
addition to
individual
characteristics such as
deprivation)
of receipt of
chemotherapy.
presence of metastatic disease at
diagnosis, IMD score (Scotland) and
health board.
Pitchforth,
‘02 [43]
Scotland Scottish Cancer
Registry ’92 to ‘96
linked to the
Scottish Morbidity
Record of inpatient
and day cases
(SMR01).
7,303 Colorectal cancer participants
(histologically or clinically confirmed
not specified). Cases diagnosed at
post-mortem were excluded.
Rurality and
distance to
hospital of first
admission.
Odds of receipt
of chemotherapy
within 6 months
of first admission
by hospital and
by population
density (rurality).
Multi-level regression, adjusted for
age, sex, comorbidity, type of
admission, death within first 6
months (as a marker of severity
of illness) and deprivation. Participants
were nested within areas, within
hospitals. Distance was treated as
an effect modifier. DepCat
deprivation score.
Units which only rarely offered
treatment were excluded.
Rich, ‘11 [39] England England NLCA and
Hospital Episode
Statistic (HES)
data Jan ‘04-
Dec 31 ‘08
7,845 Histologically confirmed SCLC
participants. Units which only rarely
offered treatment were also excluded
It was not stated whether cases diagnosed
at post-mortem were included.
Hospital trust Odds of receipt of
chemotherapy by
hospital healthcare
boundary
Multilevel logistic regression adjusted
for age, sex, deprivation, performance
status and stage and stratified by
Charlson score of comorbidity.
Townsend deprivation index.
Before and After Study
Chamberlain
‘14 [30]
England and Wales IMS Health data Unknown number of individuals, data
based on prescribing per head of
population for England and Wales
Introduction of
the Cancer
Drugs Fund
Receipt of
chemotherapy
Mg per 1000 population plotted using
moving averages. Negative binomial
regression. No deprivation score.
Stephens and
Thomson,
‘12 [33]
England IMS Health,
England ‘09-‘11
Participants: All prescriptions of the five
most commonly prescribed Cancer Drugs
Fund drugs 2011. Likely included
histological and clinically confirmed cases
though not stated. Death certified only
cases excluded. No units were excluded
from analysis due to small numbers
of cases.
Health authority Mean volume, per
head of population
of prescribed
cancer drugs fund
chemotherapy in
one year, by health
authority. Variation
expressed as 90th
to 10th percentile
differences.
Mean volumes dispensed for each
drug (mg/ head population).
Variation between SHAs: differences
between the 10th and 90th percentile
for each drug. No deprivation score.
Correlational Studies
Richards, ‘04 [6] England IMS data for 16
NICE-approved
cancer drugs,
England NHS
IMS data for 16 NICE-approved cancer
drugs. Death certified only cases were
excluded. Likely included histological and
clinically confirmed cases though not
stated. No units were excluded from
analysis due to small numbers.
Cancer network Mean volume of
prescribed
chemotherapy by
cancer network.
Variation demonstrated
by 90th to 10th
percentile differences.
Mean prescribed volume (mg) per
head of population per cancer
network. Networks compared
using 90th: 10th ratios. No
deprivation score.
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‘NICE GATE adapted quality appraisals’ are presented
in Additional file 4: Table S2–S8. Areas of potential selec-
tion bias, such as moving residence between cancer regis-
tration and treatment (cross-border flows) or the use of
the ‘nearest’ geographical treatment centre to calculate
distance, which may not be the treating hospital, was
poorly considered in the majority of studies. Other poten-
tial selection biases included variability in the criteria for
chemotherapy or poorly defining the population eligible
for treatment in different geographical areas, inappropri-
ately inflating or deflating some trusts/networks/SHA pa-
tient denominators. Finally, the exclusion of missing data
may also introduce bias.
Table 2 Key Findings for the influence of time and distance to
cancer treatment centre on chemotherapy access
Study Un-adjusted OR (CI) Adjusted OR
for receipt of
chemotherapy (CI)
P-value
Campbell
‘02 [29]
Medians and
interquartile range
shown. No
unadjusted
ORs presented.
Lung Cancer: P value
(global)
≤5 km: 1.0 0.299
6-37 km: 1.38
(0.61 to 3.14)
P value
(trend)
38-57 km: 1.93
(0.98 to 3.83)
0.166
≥58 km: 1.43
(0.71 to 2.85)
Colorectal Cancer: P value
(global)
≤5 km: 1.0 0.578
6-37 km: 1.27
(0.66 to 2.45)
P value
(trend)
38-57 km: 0.91
(0.48 to 1.73)
0.517
≥58 km: 1.37
(0.74 to 2.53)
Crawford
‘12 [40]
Not shown Rectal Not stated
Quartile 1: 1.0
Quartile 2: 0.702
(0.299 to 1.647)
Quartile 3: 0.858
(0.402 to 1.833)
Quartile 4: 1.058
(0.521 to 2.149)
Colonic
Quartile 1: 1.0
Quartile 2: 1.310
(0.730 to 2.352)
Quartile 3: 0.941
(0.540 to 1.639)
Quartile 4: 1.024
(0.617 to 1.697)
*adjusted for age and
sex for stage 4 rectal
cancer and colonic
cancer
Crawford
‘09 [36]
Not shown Quartile 1: 1 -
Quartile 2: 1.14
(0.96 to 1.34)
Not stated
Quartile 3: 1.31
(1.11 to 1.55)
Q3 P < 0.01
Quartile 4: 1.12
(0.95 to 1.32)
Not stated
Jones
’08 [31]
Not shown Breast
Quartile 1: 1.0 -
Quartile 2: 1.1
(0.95 to 1.2)
Not stated
Table 2 Key Findings for the influence of time and distance to
cancer treatment centre on chemotherapy access (Continued)
Quartile 3: 1.1
(1.0 to 1.2)
Q3 P < 0.05
Quartile 4: 0.977
(0.89 to 1.1)
Not stated
Colon
Quartile 1: 1.0 -
Quartile 2: 1.1
(0.95 to 1.2)
Not stated
Quartile 3: 0.89
(0.79 to 1.0)
Not stated
Quartile 4: 0.882
(0.78 to 1.0)
Not stated
Rectum
Quartile 1: 1.0 -
Quartile 2: 1.1
(0.97 to 1.3)
Not stated
Quartile 3: 1.1
(0.94 to 1.3)
Not stated
Quartile 4: 0.828
(0.72 to 0.96)
Q4 P < 0.01
Lung
Quartile 1: 1.0 -
Quartile 2: 0.98
(0.88 to 1.1)
Not stated
Quartile 3: 0.97
(0.88 to 1.1)
Not stated
Quartile 4: 0.703
(0.63 to 0.79)
Q4 P < 0.01
Ovary
Quartile 1: 1.0 -
Quartile 2: 1.0
(0.86 to 1.2)
Not stated
Quartile 3: 0.99
(0.84 to 1.2)
Not stated
Quartile 4: 1.0
(0.88 to 1.2)
Not stated
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Narrative Synthesis
Since meta-analysis was not possible due to the hetero-
geneity of included studies, a narrative synthesis relying
more heavily on those studies with strong reporting and
methodological quality follows.
Distance travelled/travel time
Four studies examined distance or travel time and
chemotherapy receipt (lung and colorectal cancer). No
evidence of an association was demonstrated for dis-
tance to treatment centre and receipt of chemotherapy
in a study based on low numbers (only 77 lung cancer
patients and 114 colorectal cancer patients received
chemotherapy). (15) Of three studies examining travel
time to centre and receipt of chemotherapy, one study
found no evidence of an association for colorectal cancer
chemotherapy [40], but the remaining two studies had
limited single quartile associations, which conflicted in
the direction of their association [31, 36]. The largest
study considered multiple cancer types [31] and found
evidence of an association of reduced receipt of chemo-
therapy in the most distant category of time to treatment
for two cancer types: Rectal (OR 0.8, 95 % CI 0.7 to 1.0
for the furthest distance quartile) and Lung cancer (0.7,
95 % CI 0.6 to 0.8, third most distant quartile). No test
for trend was performed. The odds of receiving chemo-
therapy for small cell lung cancer were found to be
greater for the third travel time quartile in a different
study [36], OR 1.3, 95 % CI 1.1 to 1.6, with no other
quartiles showing a statistically significant difference in
receipt of chemotherapy and no test for trend.
Rurality
There was no good evidence of an effect of ‘rurality’ on
receipt of chemotherapy for colorectal cancer with three
studies (two of which overlapped for two years of regis-
try data) showing statistically non-significant trends of a
positive association of increasing rurality with receipt of
chemotherapy [41, 43]. Although one study appreared to
show later cancer stage at presentation and poorer sur-
vival for rural popuations of men with prostate cancer,
the disease stage was not adequately adjusted for and
the “percentage of patients undergoing chemotherapy or
watchful waiting” was the same same between the rural
and urban populations (p = 0.12) [45]. However, the
study did show a marginal difference in receipt of hor-
monal therapy between the rural Highlands and the
Western Isles and the more urban Lothian (No adjust-
ment by disease stage). The Highlands and Western Isles
received less hormonal therapy, 16 % v 19 % respectively,
P = 0.042 [45].
Healthcare boundaries
Country
Only one study considered inter-country variation in can-
cer prescribing the UK. (Chamberlain et al.) [30] Prescrib-
ing of some high-cost cancer drugs was found to be up to
seven times higher in England than in Wales. Only three
of the fifteen drugs reviewed showed higher prescribing in
Wales, compared with England- all three were drugs re-
leased around the time of the introduction of the Cancer
Drugs Fund in England and were later found to be cost ef-
fective [30]. Results were not case-mix adjusted, but com-
pared per 100,000 head of population only.
Strategic Health Authority (SHA, England) or Health Board
(Scotland)
All four reports considering SHA-level variation found evi-
dence of differences in cancer prescribing [33, 35, 37, 42].
Table 3 Key Findings for the influence of rural residence on chemotherapy access
Study Un-adjusted OR (CI) Adjusted OR for receipt of chemotherapy (CI) P-value
Pitchforth ‘02 [43] Numbers presented, but no unadjusted
ORs presented
Rurality: adjusted OR 1.25 (0.99 to 1.51) Not stated
A post-hoc analysis of the effect of distance, grouped
as <95 km and ≥95 km (straight line distance) and an
interaction term for ‘no-cancer’ hospital. The results were
“not statistically significant” although it is not shown.
McLeod ‘99 [41] Rurality: 0.77 (0.63 to 0.95) Rurality: 0.88 (0.71 to 1.10) Not stated
Laing ‘13 [45] No OR presented, Read from figure: 3 %
(rural) compared with 2 % (urban) p = 0.12.
Not adjusted 0.12
Table 4 Key Findings for the influence of country on treatment and access to chemotherapy
Chamber-lain ‘14 [30] Chemotherapy prescribing volume ratios
(PVR) compared for 15 drugs by country
(England v Wales)
Not adjusted P values pertain to receipt of one named
chemotherapy in England compared with
the same chemotherapy in Wales
e.g. Bevacizumab PVR =3.28 (2.59 to 4.14)
P < 0.001
For a full list of all 15 drugs please refer to the paper.
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Jack et al. [37] was the only included study which fully
adjusted for case-mix (age at diagnosis, stage, histo-
logical sub-type, deprivation quartile and gender) and
found rates of chemotherapy varied between 26 SHAs
from 4 to 17 %. No test for statistical significance was
performed for receipt of treatment by SHA.
Cancer Network
Cancer network level variation in chemotherapy prescribing
was found in all studies in which it was examined [6, 28,
34, 38]. Only two studies quantified the inter-network vari-
ation with summary statistics, rather than a range. A chi-
squared test for heterogeneity between cancer networks
was performed (χ2 = 927.5, P < 0.001) in one study (8)where
there was a more than four-fold difference between the
lowest adjusted proportion receiving chemotherapy (6.1 %)
and the highest (27.7 %). Variation was also expressed as a
ratio of the 90th percentile to the 10th percentile of
volumes prescribed in another: the findings suggested
a range for inter-network variation from 2.6 fold variation
(Rituximab) to an 11.6 fold variation (Temozolamide) [6].
Adjusted ORs for the most recent NLCA data, resulted in
no evidence of a statistically significant different odds of
receiving any chemotherapy in patients with Small Cell
Lung Cancer (SCLC) in any cancer network, with the
exception of one network (OR 1.9, 95 % CI 1.2 to
3.0). However, a much greater number of networks
were statistically significantly different from the whole
lung cancer audit population in the odds of receiving
chemotherapy for Non-Small Cell Lung Cancer
(NSCLC) (Stage IIIb/IV PS 0 or 1). Nine (of 30) can-
cer networks had statistical evidence to reject the
null, with a range of 0.4 (0.3 to 0.6) to 1.9 (1.3 to
2.8) indicating nearly five times (4.7) greater prescrib-
ing in the highest, compared with the lowest prescrib-
ing cancer network [46].
Table 5 Key Findings for the influence of designated Cancer Network of treatment and access to chemotherapy
Study Un-adjusted OR (CI) Adjusted OR for receipt of chemotherapy (CI) P-value
Beckett ‘12 [34] Not clearly stated Not stated in text- read from figure: Range of
network adjusted OR of receipt of chemo in
SCLC 2.1 (CI 1.6 to 2.75) to 0.55 (0.49 to 0.75)
Not stated
Patel ‘07 [38] Cancer network Cancer network P < 0.001
A 18.0 A 18.0
B 18.2 B 20.5
C 18.6 C 20.7
D 17.4 D 18.6
E 18.6 E 20.5
F 24.1 F 27.7
G 17.4 G 16.6
H 10.8 H 10.3
I 10.4 I 10.9
J 18.0 J 16.9
K 7.8 K 6.1
L 15.0 L 12.6
M 14.3 M 14.2
Richards ‘04 [6] Variation by cancer network measured for
each drug and adjusted by network size only.
Values given per drug for variation across
networks including 25 th/75 th percentile,
90 % ILE/10 % ILE, mean, median, maximum
90-percentile to/10-percentile volume ratios
for drugs across cancer networks:
Not performed
Rituxumab: 2.61, Imatinib 2.90, Gemcitabine
2.99, Fludarabine 3.15, Docetaxel 3.29,
Capecitabine 3.60, Oxaliplatin 3.72, Irinotecan
3.73, Paclitaxel 3.78, Trastuzumab 4.25,
Vinorelbine 8.13, Pegylated Liposomal
Doxorubicin 9.69, Temozolamide 11.61,
Cisplatin 2.26, Epirubicin 2.36, Doxorubicin 2.68
NLCA ‘13* [28] Numbers and percent of patients receiving
chemo-therapy per network. Range: SCLC
49.3 % to 80.4 %, NSCLC 43.6 % to 70.9 %
Only one network was statistically significantly
different to the whole NLCA population with
SCLC: OR 1.88, 95 % CI 1.19 to 2.97. Nine cancer
networks were statistically significantly different
to the whole population odds for receipt of
chemotherapy in NSCLC, with a range of 0.41
(0.27 to 0.60) to 1.93 (1.32 to 2.83) (in 2012).
Not stated
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Acute hospital trust
All four studies considering geographical variation at the
Trust level also found evidence of variability in chemo-
therapy prescribing. There were, however, no summary
values for the degree of heterogeneity or variation be-
tween the trusts in any of the reviewed studies. Two
cohort studies [39, 41] assessed variability in access to
chemotherapy for colorectal and lung cancer and found
persistent variability, with the percentage of patients re-
ceiving chemotherapy per trust ranging from 0 to 68 %,
with a median of 3 % in McLeod [41], compared with a
range of 14 to 86 % (median of 62 %) in Rich et al. [39]
Table 7 Key Findings for the influence of designated Acute Trust of treatment and access to chemotherapy
Study Un-adjusted OR (CI) Adjusted OR for receipt of chemotherapy (CI) P-value
Monkhouse ‘12 [32] Not clearly presented. A table presents time to
definitive oncology by cancer site for hib and
spoke hospitals, however it is not entirely clear
what the P value pertains to. The authors also
note that “some different chemotherapy regimes
take variable lengths of time so Table 4 is for
illustrative purposes only”.
No evidence of adjustment -
McLeod ‘99 [41] Not quoted. Text states: “Without adjusting for
patient, area and hospital level characteristics
there was significant variation between both
area of residence and hospital of first admission.
Variation between hospitals was over six times
that observed between areas.”
58 Scottish Hospital point estimates (with 95 % CI)
for probability of receipt of chemotherapy presented
in a figure.
Not stated
OR of receipt chemotherapy by hospital (from figure):
range ~ OR 0.55 to 7.5.
NLCA* ‘13 [28] Numbers and percent of patients receiving
chemo-therapy per acute trust. Range (in trusts
treating >10 SCLC cases): SCLC 20.8 % to 92.9 %,
NSCLC 9.3 % to 45.9 %
Adjusted odds ratios for receipt of chemotherapy in
SCLC by each acute trust (for trusts with >10
SCLC cases), compared with the whole NLCA population,
showed a range of 0.24 (95 % CI 0.09 to 0.67) [18 cases]
to 8.44 (95 % CI 1.79 to 39.80) [12 cases] with 14 trusts
having statistically significant odds ratios demonstrating
difference from the null- NLCA overall population estimate.
Adjusted odds ratios for NSCLC by trust demonstrated a
range of OR 0.20 (95 % CI 0.08-0.54) [25 cases] to 7.51
(95 % CI 1.69 to 33.4)[19 cases]. 27 trusts had statistically
significant different odds of chemotherapy compared
to the whole NLCA population for NSCLC.
Not stated
Rich ‘11 [39] Not stated Overall proportion receiving chemotherapy across
NHS trusts was 0.61.
P < 0.001
Range 0.14 to 0.86 (interquartile range 0.53 to 0.71).
Adjusting for all patient features there was significant
variation (P < 0.001)Trust odds ratios ranged from 0.03
(0.014 to 0.07) to 4.47 (1.46 to 13.72) with an
interquartile range of 0.42 to 1.0.2
Table 6 Key Findings for the influence of designated Strategic Health Authority/Health Board of treatment and access to
chemotherapy
Study Un-adjusted OR (CI) Adjusted OR for receipt of chemotherapy (CI) P-value
Cartman ‘02 [35] The proportion of patients having chemotherapy
was 9.5 % (range 5 % to 12.9 %)
Adjusted analysis performed for survival
regression analysis only
Not performed
Jack ‘03 [37] Median % and range of chemo-therapy by health
authority: chemo-therapy alone: 4 %, range 3-9 %,
any chemo-therapy median 8 %, range 4-17 %.
Odds of chemotherapy if first hospital
visited was a radiotherapy centre: OR 1.38
(1.06 to 1.80).
P = 0.018
Paterson ‘13 [42] Unadjusted OR not given Health board A, OR 1.00 (0.89, 1.38) (of any
chemotherapy), Health board B OR 1.11
(0.89 to 1.38) P 0.36, Health board C OR
1.07, (0.91 to 1.25)
Health Board B 0.36
Health Board C 0.42
Stephens ‘12 [33] From figure. Not performed Not performed
Everolimus 0.2 to 2.1 mg per head pre CDF across
five SHAs reduced to 0.55 to 1.45 post-CDF; Lapatinib
0.05 to 2.0 pre-CDF and 0.70 to 1.25 after; Sorafenib
0.08 to 2.5 pre-CDF and 0.45 to 1.3 after; Bevacizumab
and Cetuximab 0.25 to 2.1 pre and 0.45 to 2.0 post-CDF.
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for each cancer type. Adjusted odds ratios for receipt of
chemotherapy in SCLC by each acute trust (for trusts
with >10 SCLC cases), compared with the whole NLCA
population, showed a range of 0.2 (95 % CI 0.1 to 0.7) to
8.4 (95 % CI 1.8 to 39.8) with 14 trusts having statisti-
cally significant odds ratios, rejecting the null of no dif-
ference between the trusts and the summary
chemotherapy estimate for NLCA data [28]. 27 trusts
showed statistically significant differences from the null
for NSCLC (adjusted odds ratios demonstrated a range
with OR 0.2 (95 % CI 0.1-0.5) to 7.5 (95 % CI 1.7 to
33.4)). Monkhouse et al. only compared two acute trusts
performance, intending to represent a ‘hub’ and ‘spoke’
model of cancer care. When comparing receipt of
chemotherapy alone it was not clear there was any sta-
tistically (or clinically) significant difference in receipt of
treatment between the hub and spoke for oesophageal
cancer, but there was uncertain evidence for a difference
for gastric cancer (unclear data presentation) [32].
Discussion
Main findings
There is clear evidence of variation in chemotherapy use
by geographical area, implying that even in the post NICE
era, a postcode lottery in prescribing is still present. The
cause of the geographical variation appears to be associ-
ated with healthcare boundaries, i.e. cancer network, and
SHA level, associated with policy makers, commissioners
and providers, rather than ‘natural geographic factors’
such as time or distance to chemotherapy centres, or rur-
ality of the patient population. The best quality, case-mix
adjusted studies demonstrate a 4–5 fold difference in
chemotherapy receipt by network [38, 46].
Strengths and Limitations (study and synthesis level)
Strengths of this review include the use of a systematic
methodology to identify all relevant articles, including
peer-reviewed, grey-literature and citation searching.
There are no other systematic reviews pertaining to cancer
drugs access in the NHS, despite the importance of this
area for quality and equitable care in the NHS. Strengths
at the study-level are the number of studies published in
peer-reviewed sources which have attempted to adjust for
differential case-mix.
The major limitation of this review was the challenge
of designing a sufficiently inclusive search strategy in an
area that has no pre-existing search filters. We were also
unable to conduct a meta-analysis due to the heteroge-
neous study designs, which lack a unifying measure of
geographical variation and variably adjusted for case-mix
or stratified for deprivation. Arguably, by making the
search strategy as inclusive as possible to capture all bar-
riers to chemotherapy access, the search specific to
geographical barriers did not use specific geographic key
words and therefore may have missed some papers.
Confounding
The most significant limitation of the included studies is
the absence of case-mix adjustment, particularly stage
and performance status. Those studies with no case-mix
adjustment risk introduced bias where apparent differ-
ences (or lack of differences) between healthcare areas
may refect differing health need in the study population.
This bias may under-or over-estimate the relationship
between geography and receipt of chemotherapy. Many
studies adjusted for deprivation [29, 31, 37, 38, 40]; how-
ever, it is uncertain whether adjusting for this potential
confounder may in fact artificially reduce and mask the
association with geography and likelihood of receipt of
chemotherapy.Stratifying by deprivation [36, 40] may
have been a more appropriate way to accommodate the
potentially modifying variable. In addition, studies used
different deprivation indices (Carstairs, DepCat, IMD (or
Scottish IMD) for adjustment. While these scales are
similar, they have differing underlying assumptions,
which may marginally contribute to differing findings.
Finally, studies which are not based on population-based
denominators, such as acute trusts, where the denomin-
ator reflects differential referral patterns, may result in
non-equivalent populations which are challenging to
compare. The review has therefore focused on cancer
networks and health authority level data which have
more comparable populations. The minor variations in
study populations (e.g. uncertain use of DCO cases, restric-
tion of included centres by size) do not clealy map to differ-
ences in outcome results. The differences clearly may
contribute to a risk of bias and therefore studies are com-
bined narratively, rather than statistically. Finally, although
there are observed differences in chemotherapy utilisation,
these differences cannot be translated into clinically ‘good’
or ‘bad’ outcomes. Outliers with high or low chemotherapy
usage may both reflect poor clinical care [5, 6].
Comparison with previous literature
Despite the number of papers describing variation nation-
ally and internationally there have been no systematic re-
views establishing the obstacles and facilitators to access
to cancer drugs in the NHS or in any other publicly-
funded health systems. One recent Canadian literature re-
view [19] described 32 studies pertaining to inequitable
access to cancer care (not solely pharmaceuticals) associ-
ated with geography including: variability between geo-
graphical regions affecting access to cancer treatments,
rural vs urban barriers and distance/time travelled.
Regional access to chemotherapy by healthcare boundar-
ies for lung cancer was shown to vary between studies,
supporting our review findings [19]. This review also
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described an association between greater distance to a
cancer centre and reduced access to chemotherapy and
palliative radiotherapy. Neither of the two papers refer-
enced in the article provide evidence of an association be-
tween increasing distance and decreasing chemotherapy
access, although there is an association with radiotherapy
[48, 49]. The international literature also finds evidence of
variability in chemotherapy access by healthcare boundar-
ies, with less papers considering ‘natural’ factors of time or
distance to treatment centre specifically [50].
The most comparable UK literature includes a recent
review [2] which covers variability in access to NICE
recommended pharmacotherapy, (not solely those spe-
cific to cancer). The literature review summarises some
of the potential causes for the ‘gap’ between recom-
mended and actual cancer prescribing in the UK, such
as gaps in molecular testing by healthcare region (e.g.
tests for the Epidermal Growth Factor Receptor [EGFR]
mutation which is required before the prescription of
some newer anti-cancer drug prescribing). Widely cited,
grey literature UK publications prior to this review,
which have been excluded due to inadequate outcome
measures [51, 52], may have been misleading, having no
case-mix adjustment and comparing geographical areas
across different time periods, rendering the apparent
three-fold (Scotland) and five-fold (Wales) reduction in
access to chemotherapy compared with England hard to
interpret. However, a peer-reviewed study, released in
2014 supported evidence of growing inter-country vari-
ation in chemotherapy prescribing between England and
Wales following the introduction of the Cancer Drugs
Fund (in England, not Wales) with an up to seven-fold
difference in prescribing of chemotherapy [30].
Implications for research and practice
International data have shown the UK to have a lower
than average adoption of cancer drugs released in the
last five years, when compared with other high-income
countries [5]. In 2010 the UK government established
the Cancer Drugs Fund to address this seeming ‘drugs
shortfall’ in England. However, the devolved UK coun-
tries of Northern Ireland, Scotland and Wales did not
introduce equivalent Cancer Drugs Funds. These differ-
ent policy directions will logically increase the geograph-
ical variation between UK countries. The results of this
review lend weight to the evidence that variation in
chemotherapy prescribing is occurring at different
healthcare boundaries, such as the variation in prescrib-
ing between England and Wales [30] and these may be
more important policy areas to intervene for equitable
prescribing than adjusting for time and distance trav-
elled to cancer treatment centres. Distinguishing be-
tween explicit policy decisions which lead to differential
prescribing and implicit conventions, such as local
individual prescriber variation is important to ensure
equity of access to chemotherapy. There are limited lon-
gitudinal analyses of variability in access to cancer drugs
over time, which could improve understanding of the ef-
fects of various health reforms on utilisation of cancer
drugs. The study of geographical variation would benefit
from a standardised methodology and outcome mea-
sures for the conduct of studies, so that future studies
may synthesise summary estimates of variation.
System process factors, including multi-disciplinary
meetings, the role of assigned specialists, and cancer
nurse specialists should be explored [53–56] as potential
sources for variation in prescribing by geographical re-
gion. Finally, once variation in chemotherapy prescribing
has been identified by geographical region, as in this re-
view, the clinical significance of that variation, where
both under- or over-use may be problematic, needs to
be considered in the context of overall survival.
Conclusion
Despite important heterogeneity in the included
reviewed studies, there is consensus that there is vari-
ability in chemotherapy prescribing between geograph-
ical areas even after case-mix adjustment. Evidence that
variation is greatest for NHS healthcare boundaries, ra-
ther than natural geographical entities, such as rurality,
suggests that local treatment habits, capacity and policy
may be more influential than natural geographical bar-
riers to access.
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